Replies to post #109321 on Amarantus Bioscience Holdings Inc (AMBS)

[brharris]

What had actually been said:

"Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"

and the follow up:

@G_Commish: @nomorefor That's correct. We will not be marketing for RUO. We will be conducting business development w/ pharma customers. Very different



No where has GC said no revenue from the RUO. GC only made the clarification in his tweet about what the marketing can legally be called.

[Solantey]

Expecting a bottom for $AMBS just north of a nickel (.052) before the end of the year (mid November).

Lower if the market correction accelerates.

Best of luck in the market to everyone.